MCL1 and neoplasm: Combining BH3 mimetics has also emerged as a promising strategy to target BCL-2 protein-mediated resistance and enhance tumour cell killing, with early in vitro studies showing that MCL-1 knockdown overcomes ABT-737 resistance [76].